MedTrace Logo

Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

NCT03139916 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-05-16

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of drugs with radiation as a possible treatment for Glioblastoma.

The drugs involved in this study are:

* Bavituximab
* Temozolomide

Conditions

Interventions

DRUG

Temozolomide

Temozolomide causes cell death and shrinks and kills the cancer cells

DRUG

Bavituximab

Bavituximab may activate (cause) the immune system to attack the cancer cells

RADIATION

Radiation

Radiation causes cell death and shrinks and kills the cancer cells.

Sponsors & Collaborators

Principal Investigators

  • Elizabeth R Gerstner, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2022-08-31
Completion
2022-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139916 on ClinicalTrials.gov